LIFEMD, INC. (LFMD) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.22%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -150.29×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 4.22% | Share-based compensation / revenue. Period ending 2026-06-30. $8.09M ÷ $191.59M × 100 ≈ 4.22% |
| Interest coverage · 12 months | -150.29× | Operating income ÷ reported interest expense. $-20.20M ÷ $134.41K ≈ -150.29× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 191.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 8.09M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -20.20M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 134.41K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $191.59M | $8.09M | $-20.20M | $134.41K | (m) | 4.22% | -150.29× | Reported |
| 2026-03-31 | (m) | $193.33M | $9.40M | $-15.42M | $840.85K | (m) | 4.86% | -18.34× | Reported |
| 2025-12-31 | (m) | $194.06M | $10.50M | $-7.67M | $1.36M | (m) | 5.41% | -5.64× | Reported |
| 2025-09-30 | (m) | $246.48M | $10.95M | $-5.29M | $2.17M | (m) | 4.44% | -2.44× | Reported |
| 2025-06-30 | (m) | $245.56M | $10.14M | $-2.03M | $2.46M | (m) | 4.13% | -0.83× | Reported |
| 2025-03-31 | (m) | $234.01M | $12.24M | $-7.43M | $2.33M | (m) | 5.23% | -3.19× | Reported |
| 2024-12-31 | (m) | $212.45M | $12.23M | $-16.14M | $2.18M | (m) | 5.76% | -7.40× | Reported |
| 2024-09-30 | (m) | $193.06M | $12.78M | $-19.33M | $2.19M | (m) | 6.62% | -8.83× | Reported |
| 2024-06-30 | (m) | $178.28M | $13.70M | $-19.22M | $2.35M | (m) | 7.68% | -8.19× | Reported |
| 2024-03-31 | (m) | $163.56M | $12.37M | $-17.81M | $2.81M | (m) | 7.56% | -6.34× | Reported |
| 2023-12-31 | (m) | $152.55M | $12.49M | $-14.49M | $2.60M | (m) | 8.19% | -5.58× | Reported |
| 2023-09-30 | (m) | $135.81M | $10.73M | $-22.69M | $2.82M | (m) | 7.90% | -8.05× | Reported |
| 2023-06-30 | (m) | $128.61M | $10.75M | $-25.18M | $2.24M | (m) | 8.36% | -11.26× | Reported |
| 2023-03-31 | (m) | $123.12M | $11.93M | $-33.19M | $1.37M | (m) | 9.69% | -24.19× | Reported |
| 2022-12-31 | (m) | $119.03M | $13.73M | $-43.45M | $1.28M | (m) | 11.54% | -34.05× | Reported |
| 2022-09-30 | (m) | $118.33M | $15.94M | $-49.23M | $585.97K | (m) | 13.47% | -84.01× | Reported |
| 2022-06-30 | (m) | $111.87M | $15.71M | $-55.00M | $2.28M | (m) | 14.05% | -24.14× | Reported |
| 2022-03-31 | (m) | $103.72M | $14.22M | $-55.49M | $3.05M | (m) | 13.71% | -18.20× | Reported |
| 2021-12-31 | (m) | $92.88M | $12.07M | $-54.30M | $3.02M | (m) | 13.00% | -17.98× | Reported |
| 2021-09-30 | (m) | $78.35M | $9.74M | $-72.96M | (m) | (m) | 12.43% | (m) | (m) |
| 2021-06-30 | (m) | $64.41M | $22.99M | $-80.91M | (m) | (m) | 35.70% | (m) | (m) |
| 2021-03-31 | (m) | $51.19M | $20.89M | $-68.00M | $1.01M | (m) | 40.80% | -67.06× | Reported |
| 2020-12-31 | (m) | $37.29M | $18.66M | $-57.82M | $1.67M | (m) | 50.02% | -34.67× | Reported |
| 2020-09-30 | (m) | $15.96M | $17.09M | $-26.01M | $1.64M | (m) | 107.09% | -15.83× | Reported |
| 2020-06-30 | (m) | $8.08M | $894.63K | $-6.45M | $1.48M | (m) | 11.07% | -4.35× | Reported |
| 2020-03-31 | (m) | $1.69M | $674.51K | $-4.07M | $1.38M | (m) | 39.93% | -2.94× | Reported |
| 2019-12-31 | (m) | $83.55K | $733.22K | $-2.89M | $761.15K | (m) | 877.54% | -3.80× | Reported |
| 2019-09-30 | (m) | $10.71M | $354.74K | $-3.16M | $580.15K | (m) | 3.31% | -5.45× | Reported |
| 2019-06-30 | (m) | $10.08M | $306.24K | $-2.58M | $596.88K | (m) | 3.04% | -4.32× | Reported |
| 2019-03-31 | (m) | $9.42M | (m) | $-2.34M | $518.13K | (m) | (m) | -4.52× | Reported |
| 2018-12-31 | (m) | $8.32M | $273.57K | $-2.06M | $354.39K | (m) | 3.29% | -5.80× | Reported |
| 2018-09-30 | (m) | (m) | $511.85K | $-1.51M | $-345.00K | (m) | (m) | (m) | Reported |
| 2018-06-30 | (m) | (m) | $389.61K | $-1.34M | $-491.56K | (m) | (m) | (m) | Reported |
| 2018-03-31 | (m) | (m) | (m) | $-945.05K | $-542.38K | (m) | (m) | (m) | Reported |
| 2017-12-31 | (m) | (m) | $162.74K | $-1.07M | $100.52K | (m) | (m) | -10.62× | Reported |
| 2017-09-30 | (m) | (m) | $257.51K | $-1.58M | $683.52K | (m) | (m) | -2.31× | Reported |
| 2017-06-30 | (m) | (m) | $582.95K | $-1.52M | $692.40K | (m) | (m) | -2.19× | Reported |
| 2017-03-31 | (m) | (m) | $739.31K | $-1.44M | $694.90K | (m) | (m) | -2.08× | Reported |
| 2016-12-31 | (m) | (m) | $587.99K | $-1.17M | $48.61K | (m) | (m) | -24.16× | Reported |
| 2016-09-30 | (m) | $4.63M | $556.02K | $-737.25K | $20.23K | (m) | 12.02% | -36.44× | Reported |
| 2016-06-30 | (m) | $3.52M | $191.86K | $-511.61K | $24.66K | (m) | 5.45% | -20.74× | Reported |
| 2016-03-31 | (m) | $2.57M | $114.17K | $-375.15K | $30.07K | (m) | 4.44% | -12.48× | Reported |
| 2015-12-31 | $23.93K | $1.22M | $77.30K | $-262.22K | $37.48K | 1.96% | 6.34% | -7.00× | Reported |
| 2015-09-30 | (m) | $1.01M | $49.50K | $-136.31K | $36.57K | (m) | 4.92% | -3.73× | Reported |
| 2015-06-30 | (m) | $890.75K | $45.50K | $-287.20K | $22.40K | (m) | 5.11% | -12.82× | Reported |
| 2015-03-31 | (m) | $810.01K | $19.00K | $-345.41K | $14.67K | (m) | 2.35% | -23.54× | Reported |
| 2014-12-31 | (m) | $714.16K | $45.00K | $-530.88K | $4.68K | (m) | 6.30% | -113.36× | Reported |
| 2014-09-30 | (m) | $715.03K | $62.50K | $-672.76K | $4.55K | (m) | 8.74% | -147.86× | Reported |
| 2014-06-30 | (m) | $644.24K | $56.00K | $-708.48K | $4.29K | (m) | 8.69% | -165.11× | Reported |
| 2014-03-31 | (m) | $770.53K | $106.00K | $-653.26K | $3.86K | (m) | 13.76% | -169.11× | Reported |
| 2013-12-31 | (m) | $808.36K | $105.00K | $-546.41K | $3.38K | (m) | 12.99% | -161.42× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $673.78K | $84.00K | $-540.02K | $3.37K | (m) | 12.47% | -160.20× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Airsculpt Technologies, Inc. (AIRS) | United States | $0.146B | -27.36 |
| SBC Medical Group Holdings Inc (SBC) | United States | $0.487B | |
| Teladoc Health, Inc. (TDOC) | United States | $1.114B | -8.68 |